Source:http://linkedlifedata.com/resource/pubmed/id/18413705
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2008-5-2
|
| pubmed:databankReference | |
| pubmed:abstractText |
The corticotropin-releasing hormone (CRH) system is implicated in the pathogenesis of several psychiatric disorders, including major depressive disorder. This study was designed to evaluate the safety and efficacy of CP-316,311, a selective nonpeptide antagonist of corticotropin-releasing hormone type 1 (CRH(1)) receptors, in the treatment of recurrent major depressive disorder.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1535-7228
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
165
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
617-20
|
| pubmed:meshHeading |
pubmed-meshheading:18413705-Adult,
pubmed-meshheading:18413705-Aged,
pubmed-meshheading:18413705-Antidepressive Agents,
pubmed-meshheading:18413705-Depressive Disorder, Major,
pubmed-meshheading:18413705-Double-Blind Method,
pubmed-meshheading:18413705-Humans,
pubmed-meshheading:18413705-Middle Aged,
pubmed-meshheading:18413705-Questionnaires,
pubmed-meshheading:18413705-Receptors, Corticotropin-Releasing Hormone,
pubmed-meshheading:18413705-Sertraline,
pubmed-meshheading:18413705-Treatment Outcome
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression.
|
| pubmed:affiliation |
Pfizer Global Research and Development, M.S. 8260-2604, Groton, CT 06340, USA. brendon.binneman@pfizer.com
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|